Cellectis (CLLS) Misses Q2 EPS by 29c

Cellectis (NASDAQ: CLLS) reported Q2 EPS of ($0.80), $0.29 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $14.62 million versus the consensus estimate of $23.46 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.

You May Also Be Interested In

• IBM plunges 19% as memory capex squeeze derails Q2 earnings
• Goldman Sachs (GS) Tops Q2 EPS by $6.60, Beats on Revenue
• Goldman Sachs on JPMorgan (JPM): 'We believe the results were modestly positive'